VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to ...

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 ...

When faced with the myriad diseases and equally numerous targets for potential drugs the company could pursue, Kewalramani ...

In terms of liquidity and interest, the mean open interest for Vertex Pharmaceuticals options trades today is 82.0 with a ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best fundamental stocks to buy according to hedge funds.

A high-level overview of Vertex Pharmaceuticals Incorporated (VRTX) stock. View (VRTX) real-time stock price, chart, news, analysis, analyst reviews and more.

Vertex Pharmaceuticals encountered a challenging first quarter in 2025, as both revenue and non-GAAP profit fell short of ...

During a clinical trial, around 83% (10 out of 12) of patients who received a full dose of Zimislecel achieved complete ...

While BMO Capital Markets said that zimislecel is “highly encouraging” for type 1 diabetes, questions regarding its target ...

Vertex Pharmaceuticals may have narrowed its focus this year, but the biopharma’s decision to stick with its remaining islet ...

This was the stock's second consecutive day of gains.

Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc VRTX. Stock XNAS Rating as of Jun 27, 2025. Read Company Report Download PDF. More Actions Summary; Chart; News; Price vs Fair Value; ...